On Thursday, Shares of Apple Inc. (NASDAQ:AAPL), lost -0.50% to $122.37.
Apple will launch the next generation of its Apple TV set-top box in September, with a new remote and support for Siri voice control, online publisher BuzzFeed stated on Thursday, according to Reuters.
As has been formerly rumored, it is said to comprise an A8 processor, a touch-pad based remote that’s “drastically improved” contrast to the current version, a new operating system that supports a full App Store, developer APIs, and Siri voice control, and more on-board storage to accommodate apps. Physically, the Apple TV will take on a new, slimmer look.
Apple said it declined to comment on rumors and speculation.
The Apple TV has not been refreshed since 2013.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of NCR Corporation (NYSE:NCR), declined -9.12% to $27.61, during its last trading session.
NCR Small Business declared the launch of NCR Silver Register™, an all-in-one, tablet point-of-sale (POS) system that is built for purpose, runs NCR Silver™ in the cloud and excludes third-party user applications to assist maximize employee productivity and assist minimize security risks.
The integrated system, which operates on a closed Android platform, is ready, out of the box, with implementation software allowing for a quick set-up of NCR Silver so merchants can ring-up sales the same day. For merchants who also want to take mobile transactions, NCR Silver Register easily syncs with select Apple® devices in the cloud. This enables associates to emerge from behind the register and focus on their customers, creating opportunities to deliver the omni-channel experiences customers now expect.
NCR Silver Register’s plug-and-play functionality enables small businesses to simply turn the product on and start accepting payments within minutes. Additionally, the solid-state terminal delivers a higher level of durability – making it well-suited for larger franchises and multi-store retailers who want a complete POS system that is easy to maintain.
NCR Corporation, a technology company, provides solutions and services that enable businesses to connect, interact, and transact with their customers worldwide. The company operates through four segments: Financial Services, Retail Solutions, Hospitality, and Emerging Industries.
Finally, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), ended its last trade with 10.53% gain, and closed at $1.47.
Sunesis Pharmaceuticals stated financial results for the second quarter ended June 30, 2015. Loss from operations for the three and six months ended June 30, 2015 was $10.6 million and $19.4 million, respectively. As of June 30, 2015, cash, cash equivalents and marketable securities totaled $39.6 million.
Second Quarter 2015 Highlights
Received European regulatory guidance regarding potential marketing authorization application for Vosaroxin in AML. In July 2015, Sunesis declared that, following pre-submission advisory meetings to talk about the potential submission of a Marketing Authorization Application (MAA) for vosaroxin in Europe, the company is proceeding with an MAA filing. The MAA will focus on the indication of relapsed/refractory acute myeloid leukemia (AML) in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company’s pivotal Phase 3 study of vosaroxin in adult patients with relapsed or refractory AML.
Received feedback from FDA regarding NDA filing for Vosaroxin in AML. In July 2015, Sunesis declared that, following a recent meeting with the U.S. Food and Drug Administration (FDA), the FDA recommended that the company provide additional clinical evidence to support a future NDA submission. The company is presently evaluating and refining its plan to gain marketing approval in the U.S. based on this feedback.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
